This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.—
I must respond to the recent debate concerning the use of clindamycin in the treatment of moderately severe acne. For the past two years, I have been treating a number of patients with moderately severe acne resistant to tetracycline, minocycline, and various topical agents, with lincomycin hydrochloride monohydrate (Lincocin) (300 to 450 mg intramuscularly) at intervals of three to four weeks with improvement noted by both the patient and the doctor by the second or third injection. To date, there have been no side effects. I have also injected cystic acne lesions with triamcinolone hexacetonide (Aristospan) (5 mg/ml), diluted equal parts with lincomycin hydrochloride monohydrate with satisfactory resolution of lesions and again no side effects. For many patients who have had months of painful acne nodules, lincomycin hydrochloride monohydrate has brought welcome relief. Before we throw out a useful treatment, perhaps a change in the method of administration may
Levenson I. Treatment for Acne. Arch Dermatol. 1977;113(8):1128–1129. doi:10.1001/archderm.1977.01640080130029
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.